ERIN MENDELSOHN

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Policies to enhance patient access to medicines in Medicare; Review of proposed rule regarding testing of Medicare part B prescription drug models; Discussions related to rebates and Medicare part D - provisions related to the HHS-OIG Rebate Safe Harbor; Proposals related to amending the protected classes in Medicare; Medicare payment proposals; Medicare telehealth proposals; IVIG Medicare demonstration project; P.L. 117-169 Inflation Reduction Act - reconciliation package with provisions related to prescription drug prices, implementation, negotiation, Part D redesign, inflation penalties; Implementation of 2023 Physician Fee Schedule rule related to Part B discarded drug policy; H.R. 2666, Medicaid VBPs for Patients Act or MVP Act - issues related to value based payment arrangements; E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling; CMS Medicaid Drug Rebate Proposed Rule - issues related to best price and survey Medicare Prescription Drug Inflation Rebate Program Part B Rebatable Drug Coinsurance Reduction Drug List

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits; Administration's Global Tax Proposal; S. 866/H.R. 2673, A bill to amend the Internal Revenue Code of 1986 to enhance tax benefits for research activities - issues related to R&D amortization; H.R. 3665, To provide an enforcement of remedies against the extraterritorial taxes and discriminatory taxes of foreign countries.

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits; Administration's Global Tax Proposal; S. 866/H.R. 2673, A bill to amend the Internal Revenue Code of 1986 to enhance tax benefits for research activities - issues related to R&D amortization; H.R. 3665, To provide an enforcement of remedies against the extraterritorial taxes and discriminatory taxes of foreign countries.

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

FY2024, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; P.L. 117-328, Consolidated Appropriations Act, 2023 - provisions related to IVIG Demo, pharmaceutical issues, PDUFA and BsUFA, PIE ACT, accelerated approval pathways, clinical trial design; H.R. 5860, Making continuing appropriations for fiscal year 2024, and for other purposes;

FY2024, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations H.R. 5860, Making continuing appropriations for fiscal year 2024, and for other purposes

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; S. 652, Safe Step Act - provisions related to step therapy policy; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Awareness of Rare Disease issues related to diagnosis and care access S. 4293, Pharmacy Benefit Manager Transparency Act of 2022

Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits; Administration's Global Tax Proposal; S. 866/H.R. 2673, A bill to amend the Internal Revenue Code of 1986 to enhance tax benefits for research activities - issues related to R&D amortization; H.R. 3665, To provide an enforcement of remedies against the extraterritorial taxes and discriminatory taxes of foreign countries.

S. 866, A bill to amend the Internal Revenue Code of 1986 to enhance tax benefits for research activities - issues related to R&D amortization;

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; Modernizing and Ensuring PBM Accountability (MEPA) Act H.R.410, S.1130, Health Care PRICE Transparency Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5539, Orphan Cures Act;

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Amending P.L. 97-414, Orphan Drug Act Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act Drug pricing, including House and Senate draft bills S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy H.R. 2534, PROTECT 340B Act of 2023 S. 2333, Pandemic and All-Hazards Preparedness and Response Act H.R. 410, S.1130, Health Care PRICE Transparency Act H.R. 830, S.1375, HELP Co-Pays Act H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2670, S. 2226, National Defense Authorization Act H.R. 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act (IRA commercial spillover) H.R. 5539, Orphan Cures Act H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs H.R. 2816, The PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act S. 127, Pharmacy Benefit Manager Transparency Act S.1131, Drug Price Transparency Act of 2023 S.1339, Pharmacy Benefit Manager Reform Act S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 P.L. 111-148, Patient Protection and Affordable Care Act H.R. 5378 -The Lower Costs, More Transparency Act S. 2973 -Modernizing and Ensuring PBM Accountability Act Issues related to dengue vaccines HR 6283 Delinking Revenue from Unfair Gouging "DRUG Act" E.O. 14017, America's Supply Chains E.O. 14087, Lowering Prescription Drug Costs for Americans - issues related to CMMI modeling R.F.I. Docket Number 230831-0207, Document Number 2023-26930, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Issues related to patient access of plasma therapies; P.L. 111-148, Patient Protection and Affordable Care Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; S. 652/H.R. 2630, Safe Step Act - provisions related to step therapy policy; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; H.R. 2679, Pharmacy Benefits Manager Accountability Act - Issues related to tranparency and data disclusure for PBMs; H.R.1613, S.1038, Drug Price Transparency in Medicaid Act of 2023; S.1339, Pharmacy Benefit Manager Reform Act; H.R. 2880, Protecting Patients Against PBM Abuses Act; HR 2816, The PBM Sunshine and Accountability Act; S. 1217, Ending the Prescription Drug Kickback Act of 2023; H.R. 2534, PROTECT 340B Act of 2023; S.1131, Drug Price Transparency Act of 2023; S. 127, Pharmacy Benefit Manager Transparency Act; S.113, Prescription Pricing for the People Act; H.R. 830, S.1375, HELP Co-Pays Act; Issues/Discussions related to Senate Finance Committee PBM Framework Paper; Issues/Discussions related to Pharmacy Benefit Managers (PBMs); Discussions on Customs Border Protection changes impacting southern border plasma collections; Promoting the Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Discussions related to rare disease diagnosis and access to care; H.R. 2670, S. 2226, National Defense Authorization Act; S. 2333 Pandemic and All-Hazards Preparedness and Response Act (pre-introduction);

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; S. 652, Safe Step Act - provisions related to step therapy policy; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; Issues related to Dengue vaccines; Awareness of Rare Disease issues related to diagnosis and care access S. 4293, Pharmacy Benefit Manager Transparency Act of 2022

Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits; H.R. 1304, American Innovation and R&D Competitiveness Act of 2021 - provisions related to R&D tax issues; S.749, American Innovation and Jobs Act - provisions related to R&D tax issues; Administration's Global Tax Proposal; P.L. 117-169 Inflation Reduction Act - reconciliation package with provisions related to tax issues;

Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits; H.R. 1304, American Innovation and R&D Competitiveness Act of 2021 - provisions related to R&D tax issues; S.749, American Innovation and Jobs Act - provisions related to R&D tax issues; P.L. 117-169 Inflation Reduction Act - reconciliation package with provisions related to tax issues;

Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits; H.R. 1304, American Innovation and R&D Competitiveness Act of 2021 - provisions related to R&D tax issues; Administration's Global Tax Proposal; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to tax issues;

Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits; H.R. 1304, American Innovation and R&D Competitiveness Act of 2021 - provisions related to R&D tax issues; S.749, American Innovation and Jobs Act - provisions related to R&D tax issues; Administration's Global Tax Proposal; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to tax issues;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; P.L. 117-58 (H.R.3684), Infrastructure Investment and Jobs Act - provisions related to vial size; Proposals related to the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA) (no bills introduced); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for postapproval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3339, Capping Prescription Costs Act of 2021; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 7667, Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; S. 2164, Lower Costs, More Cures Act of 2021; H.R. 6833, Affordable Insulin Now Act; S. 2199, Insulin Price Reduction Act;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Proposed FDA guidance on gastroparesis clinical trials; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act - provisions related to lower prescription drug prices; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 - provisions related to data protection; Issues related to Dengue vaccines;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 7667, Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; S. 2164, Lower Costs, More Cures Act of 2021; H.R. 6833, Affordable Insulin Now Act; S. 2199, Insulin Price Reduction Act;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Proposed FDA guidance on gastroparesis clinical trials; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act - provisions related to lower prescription drug prices; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 - provisions related to data protection; Issues related to Dengue vaccines;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; E.O. 14081 Advancing Biotechnology and Biomanufacturing Innovation;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; P.L. 117-58 (H.R.3684), Infrastructure Investment and Jobs Act - provisions related to vial size; Proposals related to the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA) (no bills introduced); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for postapproval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3339, Capping Prescription Costs Act of 2021; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 7667, Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; S. 2164, Lower Costs, More Cures Act of 2021; H.R. 6833, Affordable Insulin Now Act; S. 2199, Insulin Price Reduction Act;

FY2023, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations - issues related to Zika funding; H.R. 8239, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; H.R. 6833 Continuing Appropriations Act 2023 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); P.L. 117-328 (H.R. 2617), Consolidated Appropriations Act, 2023 - provisions related to IVIG Demo, pharmaceutical issues, PDUFA and BsUFA, PIE ACT, accelerated approval pathways, clinical trial design;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Proposed FDA guidance on gastroparesis clinical trials; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act - provisions related to lower prescription drug prices; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 - provisions related to data protection; Issues related to Dengue vaccines;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Proposed FDA guidance on gastroparesis clinical trials; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act - provisions related to lower prescription drug prices; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 - provisions related to data protection; Issues related to Dengue vaccines;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; E.O. 14081 Advancing Biotechnology and Biomanufacturing Innovation;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; P.L. 117-58 (H.R.3684), Infrastructure Investment and Jobs Act - provisions related to vial size; Proposals related to the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA) (no bills introduced); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for postapproval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3339, Capping Prescription Costs Act of 2021; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 7667, Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; S. 2164, Lower Costs, More Cures Act of 2021; H.R. 6833, Affordable Insulin Now Act; S. 2199, Insulin Price Reduction Act;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; P.L. 117-58 (H.R.3684), Infrastructure Investment and Jobs Act - provisions related to vial size; Proposals related to the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA) (no bills introduced); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for postapproval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3339, Capping Prescription Costs Act of 2021; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; E.O. 14081 Advancing Biotechnology and Biomanufacturing Innovation;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; Bayh-Dole march-in rights policy issues; 42 USC 1320a-7b, Anti-Kickback Statute; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; P.L. 117-58 (H.R.3684), Infrastructure Investment and Jobs Act - provisions related to vial size; Proposals related to the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA) (no bills introduced); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for postapproval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3339, Capping Prescription Costs Act of 2021; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 7667, Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; S. 2164, Lower Costs, More Cures Act of 2021; H.R. 6833, Affordable Insulin Now Act; S. 2199, Insulin Price Reduction Act;

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; maximizers, alternate funding models; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Proposed FDA guidance on gastroparesis clinical trials; Bayh-Dole march-in rights policy issues; Advisory Committee on Heritable Disorders in Newborns and Children - issues related to newborn screening; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; Discussions related to Most Favored Nation/International Reference Pricing; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act - provisions related to lower prescription drug prices; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5260, Reduced Costs and Continued Cares Act - provisions related to prescription drug prices; Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA), clinical trial diversity, and accelerated approval provision; H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022 - provisions related to data protection; Issues related to Dengue vaccines;

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Policies to enhance patient access to medicines in Medicare; Discussions related to rebates and Medicare part D - provisions related to the HHS-OIG Rebate Safe Harbor; Proposals related to amending the protected classes in Medicare; H. Res. 1390, Expressing Support for the Six Medicare Protected Class; Medicare payment proposals; Medicare telehealth proposals; IVIG Medicare demonstration project; CMS Medicaid Value Based Purchasing Final Rule (CMS 2482-F); P.L. 117-169 Inflation Reduction Act - reconciliation package with provisions related to prescription drug prices, implementation, negotiation, Part D redesign, inflation penalties; Implementation 2023 Physician Fee Schedule rule related to Part B discarded drug policy; H.R. 4941, PACE Part D Choice Action of 2021 - provisions related to Medicare PDP;